BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expan
Post# of 122
(Total Views: 204)
Posted On: 06/20/2023 4:17:11 PM
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Focus with Development of New NanoAb Therapeutics
- Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs
- BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA
- The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis
- Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current levels of below $2 per share
Last September, a joint steering committee comprising professionals from BiondVax Pharmaceuticals (NASDAQ: BVXV), the Max Planck Institute for Multidisciplinary Sciences (“MPG”), and the University Medical Center Göttingen (“UMG”), made a decision. Established to guide the BVXV-MPG-UMG NanoAb collaboration, the committee decided to focus the nanosized antibody (“NanoAb”) development on other therapeutic indications in addition to COVID-19. This renewed focus would begin with the development of NanoAbs targeting immune system cytokines such as IL-17 (IL-17A, IL-17F, and IL-17A/F) for the potential treatment of psoriasis and psoriatic arthritis and IL-13 for the potential treatment of asthma (https://nnw.fm/ZKKxj ).
The committee’s decision is anchored in a five-year definitive research collaboration agreement (“RCA”) entered between BVXV, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, and its collaborators, MPG and UMG, allowing the company to exercise an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder (https://nnw.fm/cqqB6 ).
BiondVax’s decision to focus on developing additional NanoAb therapies was featured in new updated coverage by Zacks Small-Cap Research (https://nnw.fm/jCncV ). The research report highlighted the company’s recent announcement regarding its intention to exercise the option to obtain an exclusive license to NanoAbs targeting IL-17 and other system cytokines. This announcement aligns with the company’s de-risked strategy, which includes pursuing biobetter drugs for against biological targets that are already proven to exert beneficial clinical results in humans when treated with conventional monoclonal antibodies (“mAbs”). Additionally, and in line with this strategy, the company intends to capitalize on NanoAbs’ status as potential “bio-betters” that offer potential advantages over mAbs, given their stability, extremely high binding affinity with effective neutralization, and high specificity.
The company has so far gathered significant data about the potential efficacy and capabilities of NanoAbs, thanks to its preclinical in vivo proof-of-concept study evaluating the effect of its inhaled anti-COVID-19 NanoAb therapy. The study, which utilized the industry-standard Syrian hamster model of SARS-CoV-2 infection, showed that the therapy virtually eliminated the virus from the lungs (https://nnw.fm/s2jOf ), caused milder and shorter illness (https://nnw.fm/M0yRt ), and had prophylactic properties (https://nnw.fm/gCsoz ). Based on these encouraging findings, BiondVax is evaluating plans to commence a Phase 1/2a clinical trial, albeit with a keen eye on the mutation of the virus and the emergence of new variants of concern (“VoCs”).
The Zacks report lauds the shift to focus on the anti-IL-17 NanoAb as a “good decision.” By announcing its intention to exercise the option for an additional NanoAb, BiondVax is expanding its pipeline potential while mitigating certain risks to its business and diversifying its portfolio of possible block buster therapies.
Meanwhile, BVXV released its financial results for the first quarter of 2023, reporting cash and cash equivalents of $10.9 million, which analysts at Zacks estimate are sufficient to fund the company’s operations through the first quarter of 2024. An astute business practitioner as well as biotech innovator, BiondVax aims to maximize assets and increase revenues by offering its state-of-the-art cGMP manufacturing services to interested parties which could easily engender new strategic alliances as well as bolster the bottom line.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs
- BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA
- The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis
- Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current levels of below $2 per share
Last September, a joint steering committee comprising professionals from BiondVax Pharmaceuticals (NASDAQ: BVXV), the Max Planck Institute for Multidisciplinary Sciences (“MPG”), and the University Medical Center Göttingen (“UMG”), made a decision. Established to guide the BVXV-MPG-UMG NanoAb collaboration, the committee decided to focus the nanosized antibody (“NanoAb”) development on other therapeutic indications in addition to COVID-19. This renewed focus would begin with the development of NanoAbs targeting immune system cytokines such as IL-17 (IL-17A, IL-17F, and IL-17A/F) for the potential treatment of psoriasis and psoriatic arthritis and IL-13 for the potential treatment of asthma (https://nnw.fm/ZKKxj ).
The committee’s decision is anchored in a five-year definitive research collaboration agreement (“RCA”) entered between BVXV, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, and its collaborators, MPG and UMG, allowing the company to exercise an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder (https://nnw.fm/cqqB6 ).
BiondVax’s decision to focus on developing additional NanoAb therapies was featured in new updated coverage by Zacks Small-Cap Research (https://nnw.fm/jCncV ). The research report highlighted the company’s recent announcement regarding its intention to exercise the option to obtain an exclusive license to NanoAbs targeting IL-17 and other system cytokines. This announcement aligns with the company’s de-risked strategy, which includes pursuing biobetter drugs for against biological targets that are already proven to exert beneficial clinical results in humans when treated with conventional monoclonal antibodies (“mAbs”). Additionally, and in line with this strategy, the company intends to capitalize on NanoAbs’ status as potential “bio-betters” that offer potential advantages over mAbs, given their stability, extremely high binding affinity with effective neutralization, and high specificity.
The company has so far gathered significant data about the potential efficacy and capabilities of NanoAbs, thanks to its preclinical in vivo proof-of-concept study evaluating the effect of its inhaled anti-COVID-19 NanoAb therapy. The study, which utilized the industry-standard Syrian hamster model of SARS-CoV-2 infection, showed that the therapy virtually eliminated the virus from the lungs (https://nnw.fm/s2jOf ), caused milder and shorter illness (https://nnw.fm/M0yRt ), and had prophylactic properties (https://nnw.fm/gCsoz ). Based on these encouraging findings, BiondVax is evaluating plans to commence a Phase 1/2a clinical trial, albeit with a keen eye on the mutation of the virus and the emergence of new variants of concern (“VoCs”).
The Zacks report lauds the shift to focus on the anti-IL-17 NanoAb as a “good decision.” By announcing its intention to exercise the option for an additional NanoAb, BiondVax is expanding its pipeline potential while mitigating certain risks to its business and diversifying its portfolio of possible block buster therapies.
Meanwhile, BVXV released its financial results for the first quarter of 2023, reporting cash and cash equivalents of $10.9 million, which analysts at Zacks estimate are sufficient to fund the company’s operations through the first quarter of 2024. An astute business practitioner as well as biotech innovator, BiondVax aims to maximize assets and increase revenues by offering its state-of-the-art cGMP manufacturing services to interested parties which could easily engender new strategic alliances as well as bolster the bottom line.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)